Atropa belladonna
Viewing r2 — May 14, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Deadly nightshade (Atropa belladonna L., Solanaceae) is a perennial herbaceous plant producing tropane alkaloids with potent anticholinergic and deliriant properties. Its principal active constituents — atropine (racemic mixture hyoscyamine) and scopolamine — are non-selective muscarinic acetylcholine receptor antagonists.[1] These alkaloids produce their effects by blocking muscarinic receptors throughout the peripheral and central nervous systems, disrupting autonomic regulation, cognition, and sensory processing.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
atropine, scopolamine, benztropine +2 moreatropine, scopolamine, benztropine, trihexyphenidyl, diphenhydramine show less
Formally described by Linnaeus in 1753,[2] belladonna has been recognized as both poison and medicine since classical antiquity. Isolation of atropine in the 1830s proved foundational to neuroscience, enabling identification of acetylcholine as a mammalian neurotransmitter.[3] Both atropine and scopolamine remain on the WHO List of Essential Medicines,[4] while the plant itself is largely unscheduled internationally.
Subjective effects include true hallucinations indistinguishable from reality, profound amnesia, thought disorganization, and involuntary delirium. The experience is consistently described as terrifying and dysphoric — a state of complete loss of insight where users cannot distinguish drug-induced perceptions from actual events. Concurrent peripheral effects include tachycardia, extreme dry mouth, pupil dilation persisting 24–72 hours, and dangerous hyperthermia from inability to sweat.
No dependence syndrome or compulsive use pattern has been described for belladonna alkaloids; the consistently aversive character of the experience limits redosing behavior. Acute toxicity risk is critical — the margin between pharmacological effect and life-threatening poisoning is exceptionally narrow, with the EFSA acute reference dose set at 0.016 µg/kg body weight.[5] No controlled human dose-finding studies exist for whole-plant preparations, and extreme batch-to-batch variability in alkaloid content makes reliable dosing effectively impossible.
History[edit]
Traditional and historical use
Carl Linnaeus formally described Atropa belladonna in Species Plantarum (1753).[2] The genus name references Atropos, the Greek Fate who severs the thread of life; the species epithet belladonna ("beautiful woman") recalls the Renaissance practice of instilling the plant's juice into the eyes to dilate the pupils, then considered a mark of beauty.[3]
Greeks and Romans recognized the plant as a deadly poison, and ancient Egyptian medical sources document therapeutic aerosol use of related anticholinergic compounds dating back approximately 3,500 years.[6] In medieval Europe, belladonna served simultaneously as medicine, professional poison, and component of witchcraft preparations.[3] Fat-based "flying ointments" applied to mucous membranes delivered scopolamine and hyoscyamine transdermally, producing vivid hallucinations that users interpreted as supernatural flight.[6][7] Compound preparations also served as surgical anaesthetics — pharmacological analysis of medieval "soporific sponge" formulations confirms their plausibility as genuinely active preparations.[8]
Western discovery and pharmaceutical significance
Isolation of pure L-atropine from belladonna in the 1830s proved a landmark for autonomic neuroscience.[3] Atropine's capacity to block muscarinic effects of vagus nerve stimulation led directly to identification of acetylcholine as a mammalian neurotransmitter.[3] Inhaled belladonna preparations — burning dried plant material and medicinal cigarettes — were widely prescribed for asthma throughout the 19th and early 20th centuries, establishing the anticholinergic bronchodilator drug class from which modern agents like ipratropium and tiotropium descend.[6]
Modern era
Lacković (2017) documented a previously unreported tradition of intentional hallucinogenic use of belladonna berries in continental Croatia, known locally as "bunanje".[9] A survey of recreational hallucinogen users in Slovenia found knowledge of anticholinergic Solanaceae use largely lost, attributed to the experience's undesirable character and high toxicity risk.[10]
Atropine and scopolamine remain on the WHO List of Essential Medicines.[4] In 2016–2017, the U.S. FDA issued safety alerts and requested a nationwide voluntary recall of Hyland's homeopathic teething tablets after laboratory analysis found inconsistent and excessive belladonna alkaloid concentrations, with over 400 adverse events including seizures in infants reported between 2006 and 2016.[11]
Botanical Overview[edit]
Atropa belladonna L. belongs to the family Solanaceae (nightshades), which also includes Datura stramonium (jimsonweed), Hyoscyamus niger (henbane), tomato, and tobacco. The genus Atropa contains approximately four species, of which A. belladonna is the most pharmacologically significant. No subspecies or varieties are widely distinguished for psychoactive character, though alkaloid ratios vary by geographic population.citation needed
The plant is native to southern and central Europe, northern Iran, and northwestern Africa. It favours shaded, calcareous soils in woodland clearings, hedgerows, and disturbed ground. Wild populations are locally common in suitable habitat across its native range; the plant is not commercially cultivated at scale but is occasionally grown as an ornamental or in specialist botanical gardens.citation needed
A. belladonna is a branching perennial growing 0.5–1.5 metres tall, with ovate leaves up to 18 cm long arranged alternately on the stem. Flowers are solitary, bell-shaped, dull purple to greenish, approximately 2.5–3 cm in length.citation needed The fruit is the plant's most recognizable and most dangerous feature: a glossy black berry roughly 1–1.5 cm in diameter, borne in a persistent green calyx. The berries' sweet taste and resemblance to edible fruits such as blueberries or cherries make them an acute accidental ingestion risk, particularly for children.
All parts of the plant contain tropane alkaloids, with the highest concentrations in roots and ripe berries. Leaves are typically harvested during flowering for pharmaceutical preparations. The plant is perennial, regrowing from the rootstock each spring; alkaloid content varies by growth stage, soil conditions, and geographic origin.
Alkaloid Profile[edit]
The dominant alkaloids of A. belladonna are atropine (the racemic mixture form of L-hyoscyamine, produced upon extraction and processing) and scopolamine (hyoscine). Both are tropane alkaloids — bicyclic organic compounds sharing the 8-azabicyclo[3.2.1]octane skeleton — and both act as non-selective muscarinic acetylcholine receptor antagonists.[1][4] In fresh plant tissue, the natural form is (-)-hyoscyamine; racemization to dl-hyoscyamine (atropine) occurs during drying, extraction, and storage.
Scopolamine differs from atropine by a single epoxide bridge, which increases lipophilicity and blood-brain barrier penetration. This structural difference produces proportionally greater central nervous system effects — sedation, hallucinations, and amnesia — at equivalent peripheral doses.[1] The two alkaloids work in concert: hyoscyamine/atropine dominates the peripheral anticholinergic profile (tachycardia, pupil dilation, anhidrosis), while scopolamine drives the central deliriant and amnestic effects. The relative ratio of hyoscyamine to scopolamine varies across plant parts, populations, and growing conditions, modulating the balance between peripheral and central effects in any given preparation.
The European Food Safety Authority established an acute reference dose (ARfD) of 0.016 µg/kg body weight for the combined sum of (-)-hyoscyamine and (-)-scopolamine[5] — reflecting extreme potency at vanishingly low absolute doses. For a 70 kg adult, this equates to approximately 1.1 µg total.
Alkaloid content varies substantially across geographic populations, harvest timing, soil composition, and processing method. Cooked berries retain full alkaloid content,[12] and commercial preparations show extreme batch-to-batch variability. No consumer-level chemical test reliably quantifies belladonna alkaloids; confirmation requires GC-MS or LC-MS.[13]
Neuroscience[edit]
Where it acts
Belladonna alkaloids exert their principal effects through competitive blockade of muscarinic acetylcholine receptors (M1, M2, M3) across the central and peripheral nervous systems.[1][4] M1 blockade in the cortex and hippocampus drives cognitive impairment, memory disruption, and delirium. M2 blockade in the heart removes vagal braking, producing tachycardia. M3 blockade in glands and smooth muscle causes dry mouth, anhidrosis, urinary retention, and cycloplegia.[1]
Scopolamine crosses the blood-brain barrier more efficiently than atropine due to its epoxide ring, producing stronger central effects — hallucinations, sedation, and amnesia — at equivalent peripheral exposure.[1]
What it changes
Unlike serotonergic psychedelics, belladonna produces anticholinergic delirium — a state where hallucinations are indistinguishable from reality rather than recognized as drug-induced, accompanied by profound amnesia and complete loss of metacognitive insight.[1] This makes it phenomenologically distinct from any other hallucinogenic class. Behavioural modelling in zebrafish has demonstrated dose-dependent disruption of locomotion, anxiety-like behaviour, and social patterns with both atropine and scopolamine.[14]
Deliriants remain the least-studied class of hallucinogens in behavioural and neurological research.[1] No neuroimaging studies using whole belladonna plant preparations have been published. The precise neural circuit mechanisms underlying the transition from peripheral anticholinergic effects to full delirium — and why scopolamine produces proportionally greater central effects than atropine beyond simple lipophilicity differences — remain unresolved.
Subjective Effects[edit]
Belladonna intoxication is fundamentally unlike other hallucinogenic experiences. Where serotonergic psychedelics and cannabinoids preserve some degree of self-awareness, belladonna abolishes the boundary between hallucination and reality entirely. Users do not recognize their perceptions as drug-induced — they interact with shadow figures, converse with absent people, and perform actions they later cannot recall. The experience is not meaningfully dose-titrable: the gap between subthreshold exposure and full anticholinergic delirium is narrow, unpredictable, and compounded by extreme variability in plant material potency across preparations, plant parts, and individual specimens.
Belladonna occupies the same pharmacological territory as Datura stramonium (jimsonweed) and Hyoscyamus niger (henbane) — the anticholinergic deliriant Solanaceae. All three produce qualitatively similar delirium via tropane alkaloids, though differing hyoscyamine-to-scopolamine ratios modulate the balance between peripheral and central effects. Compared to serotonergic psychedelics, the experience is consistently reported as involuntary, terrifying, and amnestic rather than insightful or expansive — a distinction rooted in the receptor mechanism itself.
Effect Grid
No common dose exists for Atropa belladonna. This substance is not dose-titrable in any practical sense — no controlled human dose-finding studies have been conducted for any whole-plant preparation, and no published literature describes a reproducible dose range producing consistent, manageable effects.
All documented human exposures producing central effects have resulted in anticholinergic syndrome: delirium, amnesia, confusion, thought disorganization, tachycardia, mydriasis, temperature dysregulation, and dysphoria. The experience is consistently described as involuntary and terrifying in published case literature.
The concept of a common recreational or therapeutic dose does not apply to whole-plant belladonna preparations. Every exposure producing noticeable central effects carries substantial risk of medical emergency.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Depth perception distortion · Spatial disorientation · Auditory misinterpretation · Dreaming suppression · Visual haze / noise · Auditory distortion · Peripheral misidentification · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Vestibular distortion · Auditory hallucinations · External hallucinations · Visual processing suppression · Internal hallucinations · Shadow people · Object activation · Object transformations · Perspective hallucinations · Gustatory hallucination · Olfactory hallucination
Visual haze / noise · Auditory distortion · Peripheral misidentification · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Vestibular distortion · Auditory hallucinations · External hallucinations · Visual processing suppression · Internal hallucinations · Shadow people · Object activation · Object transformations · Perspective hallucinations · Gustatory hallucination · Olfactory hallucination
Dehydration sensation · Dizziness · Heart rate perception changes · Motor control impairment · Restlessness · Headache · Nausea suppression · Body schema distortion · Sedation · Insomnia · Nausea · Stimulation · Wakefulness · Involuntary body movements · Trembling · Vomiting · Bodily dissociation · Tactile hallucination
Restlessness · Headache · Nausea suppression · Body schema distortion · Sedation · Insomnia · Nausea · Stimulation · Wakefulness · Involuntary body movements · Trembling · Vomiting · Bodily dissociation · Tactile hallucination
Analysis suppression · Focus suppression · Information processing suppression · Memory fragmentation · Thought disorganization · Cognitive dysphoria · Cognitive fatigue · Language suppression · Suggestibility enhancement · Thought deceleration · Thought loops · Amnesia · Delirium · Delusions
Memory fragmentation · Thought disorganization · Cognitive dysphoria · Cognitive fatigue · Language suppression · Thought deceleration · Thought loops · Amnesia · Delirium · Delusions
Irritability · Anxiety suppression
Social disconnection · Depersonalization · Disinhibition · Cognitive disconnection · Identity alteration
Identity alteration
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- No data
- Withdrawal
- None
- Tolerance buildup
- —
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- atropine · scopolamine · benztropine
○ not assessed: TOL
Toxicity
No human LD50 has been established for A. belladonna or its primary alkaloids. The EFSA acute reference dose of 0.016 µg/kg body weight represents the threshold at which pharmacological effects begin in humans[5] — orders of magnitude below lethal exposure. Fatal doses in children have been documented below 10 mg atropine equivalent.[15]
The classic anticholinergic toxidrome presents as pupil dilation, tachycardia (typically 100–150 bpm), dry flushed skin, hyperthermia from anhidrosis, urinary retention, absent bowel sounds, and delirium.[16][17] Published cases include raw leaf ingestion requiring ICU admission,[16] therapeutic administration to an 11-year-old producing central anticholinergic syndrome,[17] and a Turkish case series documenting complications including acute subdural hematoma, acute pancreatitis, and rhabdomyolysis.[18] A prepared herbal extract (50 mL, equivalent to 15 mg atropine) caused anticholinergic syndrome requiring mechanical ventilation.[19]
Physostigmine (0.5–2 mg IV), a cholinesterase inhibitor that crosses the blood-brain barrier, is the specific antidote for central anticholinergic syndrome — though treatment failure has been documented.[20] Physostigmine is contraindicated in patients with AV block, asthma, or peripheral vascular disease.
Commercial belladonna-containing products present documented contamination and labelling hazards. FDA laboratory analysis of Hyland's homeopathic teething tablets found alkaloid concentrations exceeding label claims with significant batch-to-batch inconsistency; over 400 adverse events including seizures in infants were reported between 2006 and 2016.[11]
Contamination of commercial herbal teas with tropane alkaloids has caused severe anticholinergic poisoning despite GMP compliance.[21] Tropane alkaloid contamination has been documented in buckwheat flour, edible flowers, and other products when belladonna is co-harvested with edible plant material.[22] No consumer-level chemical test reliably detects belladonna alkaloids; confirmation requires GC-MS or LC-MS.[13] Specific data on pesticide residues, heavy metals, or mycotoxin contamination in belladonna preparations sold in commerce have not been identified in published literature.safety citation needed
Psychological Risks
Anticholinergic delirium is consistently described as involuntary, terrifying, and dysphoric.[16][17][18][9] Users typically have no insight during the experience and profound amnesia for it afterward. Hallucinations are true hallucinations — indistinguishable from reality — frequently involving shadow figures, phantom insects, and conversations with absent persons.[1]
The clinical presentation can be indistinguishable from acute psychosis; differential diagnosis includes neuroleptic malignant syndrome and serotonin syndrome.[23] A survey of recreational hallucinogen users in Slovenia found anticholinergic plants were specifically avoided because of the dysphoric and uncontrollable nature of the experience.[10]
Tolerance & Dependence
No published controlled studies document tolerance development to belladonna alkaloids in humans. Clinical observation suggests some peripheral tolerance to atropine's cardiac effects with repeated therapeutic exposure, but no data address tolerance to central deliriant effects specifically.
No dependence syndrome, compulsive use pattern, or withdrawal criteria have been described for belladonna alkaloids in published literature. The profound amnesia and consistent dysphoria of anticholinergic intoxication significantly limit compulsive redosing behaviour.
Drug Interactions
The most clinically significant interaction is additive anticholinergic burden with other muscarinic antagonist medications — including tricyclic antidepressants, first-generation antihistamines, phenothiazine antipsychotics, antiparkinsonian agents, and bladder antispasmodics. The mechanism is pharmacodynamic: competitive antagonism at the same muscarinic acetylcholine receptor population.[4]
CYP3A inhibitors (grapefruit juice, ketoconazole, clarithromycin, erythromycin) increase scopolamine bioavailability by approximately 42% via inhibition of first-pass hepatic metabolism, with significantly prolonged time to peak concentration.[7] This interaction applies to any scopolamine-containing preparation and is clinically relevant because it widens the exposure window for central effects.
CNS depressants (opioids, benzodiazepines, alcohol) produce additive sedation when combined with scopolamine.[24]
Cholinesterase inhibitors (physostigmine, donepezil, rivastigmine) antagonize belladonna alkaloid effects. Physostigmine is used therapeutically as the specific antidote for central anticholinergic syndrome.[16][17]
A theoretical interaction with monoamine oxidase inhibitors (MAOIs) exists on the basis of additive central mechanism, but no published case reports or pharmacokinetic studies specific to belladonna support this.citation needed
No published herb-drug interaction studies for belladonna as a whole-plant preparation have been identified; all interaction data are extrapolated from studies of the isolated alkaloids.
Contraindications
Narrow-angle glaucoma (absolute): muscarinic antagonism increases intraocular pressure, risking acute angle-closure crisis.
Cardiac arrhythmias or pre-existing tachycardia (absolute): tachycardia is a primary effect of M2 blockade; dangerous with pre-existing conduction abnormalities or tachyarrhythmias.
Prostatic hypertrophy or urinary obstruction (absolute): urinary retention is a direct consequence of M3 receptor blockade.
Pediatric populations (absolute): children are markedly more vulnerable due to lower body mass and higher CNS susceptibility. Fatal paediatric doses below 10 mg atropine equivalent are documented.[15] The sweet taste and appearance of berries present additional accidental ingestion risk.
Pregnancy (relative): both atropine and scopolamine cross the placenta; use requires clinical monitoring.[7]
Elderly patients (relative): increased sensitivity to anticholinergic cognitive effects; cumulative anticholinergic burden is associated with increased cognitive impairment risk.
Psychiatric history (relative): anticholinergic delirium may be particularly distressing in individuals with psychiatric vulnerability; presentation can mimic acute psychosis.[23]
Concurrent anticholinergic medication (relative): additive muscarinic blockade increases risk of severe anticholinergic toxicity.[4]
Preparations[edit]
No controlled human dose-finding studies exist for any whole-plant belladonna preparation. The margin between pharmacological effect and life-threatening toxicity is exceptionally narrow — the EFSA acute reference dose is 0.016 µg/kg body weight,[5] orders of magnitude below any dose associated with hallucinogenic effects. The information below describes documented preparation forms; it does not constitute dosing guidance.
Raw berries
Raw berries are the most commonly documented route of both accidental and intentional exposure. Individual berries contain variable alkaloid concentrations; fatal doses in children have been documented below 10 mg atropine equivalent.[15] The berries' sweet taste and resemblance to blueberries or cherries drives accidental paediatric ingestion. Cooked berries retain full alkaloid content; plasma atropine has been confirmed after ingestion of cooked berries.[12] Onset after oral ingestion is typically 30–60 minutes; central effects persist 4–12 hours, with pupil dilation lasting 24–72 hours or longer.
Dried leaf
Dried leaf is the traditional pharmaceutical form, used historically in asthma cigarettes and soporific preparations.[6] Alkaloid content varies substantially by harvest timing, geographic origin, and drying method. Inhalation of smoke from burning dried leaf produced bronchodilation via anticholinergic action in 19th-century medical practice. The European Pharmacopoeia includes official monographs for belladonna leaf.[5]
Tinctures and herbal extracts
Tinctures and herbal extracts concentrate alkaloids unpredictably. A prepared herbal extract (50 mL, equivalent to 15 mg atropine) caused anticholinergic syndrome requiring mechanical ventilation in an experienced herbalist.[19] Commercial extracts show extreme batch-to-batch variability, and no consumer-level test can verify alkaloid concentration.[13]
Topical ointments
Topical ointments (historical "flying ointments") applied to mucous membranes deliver scopolamine and hyoscyamine transdermally.[7] Scopolamine's confirmed transdermal absorption enables psychotropic effects without the higher fatality risk of oral dosing.[7] This route was historically favoured in medieval witchcraft preparations.[6]
Per-preparation dose tiers cannot be reliably established for belladonna due to extreme alkaloid variability across specimens and batches. Dose data for the isolated alkaloids (atropine, scopolamine) are available on their respective compound pages.
Harm Reduction[edit]
Forms & Identification
Belladonna preparations cannot be reliably assessed for potency by appearance, smell, or taste. Alkaloid concentrations vary unpredictably across plant parts, geographic populations, harvest timing, and processing methods. No consumer-level reagent test or field kit can detect or quantify tropane alkaloids — confirmation requires laboratory analysis by GC-MS or LC-MS.[13]
If encountering belladonna in commercial herbal products, a Certificate of Analysis from an ISO-accredited laboratory is the only meaningful quality indicator. Homeopathic and herbal products labelled as containing belladonna have been documented with alkaloid concentrations exceeding label claims.[11]
Guidelines
- Do not use belladonna as a recreational substance. The margin between threshold effects and life-threatening toxicity is narrower than for virtually any other psychoactive plant preparation. No controlled dose-finding data exist.
- Never combine with other anticholinergic medications (tricyclic antidepressants, antihistamines, antipsychotics), CNS depressants (opioids, benzodiazepines, alcohol), or CYP3A inhibitors (grapefruit juice, ketoconazole).
- Keep all plant material away from children. The berries' sweet taste and resemblance to edible fruits make accidental paediatric ingestion a primary risk vector.
- If you encounter belladonna in a herbal product, verify alkaloid content via an ISO-accredited laboratory Certificate of Analysis before any use.
- Cooked or processed berries retain full alkaloid content — heating does not reduce toxicity.[12]
Set & Setting
Anticholinergic delirium eliminates insight, self-awareness, and memory formation. Unlike serotonergic psychedelics, there is no "set and setting" framework that meaningfully modulates the belladonna experience. Users will not recognize that they are intoxicated, will not remember the experience, and will not be able to make rational decisions during it.
If exposure has occurred — whether intentional or accidental — the presence of a sober, informed companion who can recognize anticholinergic toxidrome signs and contact emergency services is the single most important harm reduction measure.
Aftercare & integration. Anticholinergic effects may persist for 12–24 hours after initial onset; pupil dilation can last 24–72 hours or longer. During recovery:
- Hydrate actively — anticholinergic effects impair normal fluid regulation.
- Avoid bright light — prolonged mydriasis causes light sensitivity and visual acuity suppression. Sunglasses or dim environments reduce discomfort.
- Do not drive or operate machinery until mydriasis has fully resolved and cognitive function has returned to baseline.
- Expect amnesia — most people have little or no memory of the intoxication itself. Disorientation and cognitive fog may persist for 24–48 hours after acute effects subside.
- Seek medical evaluation if tachycardia, urinary retention, or confusion persist beyond 24 hours.
Recovery & Support
Belladonna does not produce physical dependence or a withdrawal. Repeated intentional use is rare due to the consistently aversive nature of the experience.
If you or someone you know has been exposed to belladonna — accidentally or intentionally — and is experiencing ongoing physical symptoms or psychological distress:
- Poison Control (US): 1-800-222-1222 (available 24/7)
- SAMHSA National Helpline (US): 1-800-662-4357 (free, confidential, 24/7)
- NHS 111 (UK): for non-emergency medical advice after exposure
- Emergency services (all jurisdictions): if symptoms of anticholinergic toxicity are present
For individuals who have used belladonna intentionally and are considering further use, contact a healthcare provider or harm reduction service for individualised guidance.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Anticholinergic toxidrome signs include dilated pupils unresponsive to light, rapid heart rate, hot dry flushed skin, inability to urinate, confusion or agitation progressing to delirium, hallucinations, and seizures.
Immediate steps:
- 1. Call emergency services immediately. Anticholinergic poisoning can be fatal and requires hospital-level intervention.
- 2. Do not attempt to induce vomiting.
- 3. Keep the person in a cool environment — hyperthermia from anhidrosis is a primary life-threatening complication.
- 4. Prevent the person from injuring themselves during delirium — they may attempt to leave, interact with phantom objects, or behave unpredictably.
- 5. Monitor breathing and heart rate continuously until emergency services arrive.
What to tell the dispatcher: Name the substance (belladonna / deadly nightshade), estimated amount consumed, time of ingestion, and current symptoms — especially heart rate, skin temperature, and mental state. Good Samaritan laws providing legal protection for callers exist in many jurisdictions.
Reversal agent: Physostigmine (0.5–2 mg IV) is the specific antidote for central anticholinergic syndrome, administered in hospital settings only. It is not available for lay administration.
Legal Status[edit]
A. belladonna and its primary alkaloids (hyoscyamine, atropine, scopolamine) are not scheduled under any United Nations drug convention — the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, or the 1988 Convention Against Illicit Traffic. The plant is freely cultivable under international law, occupying a notable regulatory gap given its significant psychoactive and toxic potential. Atropine and scopolamine are regulated as prescription pharmaceuticals in most jurisdictions, but the plant material itself is largely uncontrolled.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Unscheduled | Not controlled under the Controlled Substances Act. The plant and all parts are legal to cultivate, possess, and distribute. FDA regulates products claiming medicinal efficacy; prescription required for pharmaceutical atropine and scopolamine formulations[25] |
| Louisiana (US state) | Restricted | Since August 2005, A. belladonna is illegal when intended for human consumption; possession for aesthetic, landscaping, or decorative purposes remains permitted[25] |
| United Kingdom | Not controlled | Not scheduled under the Misuse of Drugs Act 1971. The plant may be legally cultivated. Atropine and scopolamine require prescriptions under the Medicines Act but are not classified as controlled drugscitation needed |
| Germany | Pharmaceutical regulation | Belladonna leaf and root are available by prescription in German pharmacies. The European Pharmacopoeia includes official monographs for pharmaceutical use[5] |
| Australia | Pharmaceutical regulation | Atropine is Schedule 4 (Prescription Only Medicine) under the Poisons Standard managed by the TGA. The plant itself may be subject to state-level noxious weed legislationcitation needed |
| International treaties | Unscheduled | Not controlled under any UN drug convention (1961, 1971, or 1988). The plant occupies a regulatory gap: its alkaloids are prescription pharmaceuticals in most countries, but the plant itself is not internationally controlled |
FDA enforcement action against homeopathic belladonna products is notable. Following a safety alert in 2010 and a formal warning in 2016, the FDA requested a nationwide voluntary recall of all lots of Hyland's Baby Teething Tablets in April 2017 after laboratory analysis confirmed inconsistent and excessive belladonna alkaloid concentrations.[11]
Detection
Belladonna alkaloids are not included in standard 5-panel or 10-panel workplace drug tests. Specific analytical testing must be ordered. In a forensic case, scopolamine was detected in urine at 41 µg/L at 18 hours post-exposure (blood was negative at the same timepoint) and in hair at 0.37 pg/mg at 5 weeks post-exposure[26] — demonstrating a narrow urine detection window but significantly extended hair detection capability. Plasma atropine measurement has been used for clinical management of acute belladonna poisoning.[27]
references
- [1] ^abcdefghiLakstygal AM, Kolesnikova TO, Khatsko SL, Zabegalov KN, Volgin AD, Demin KA, Shevyrin VA, Wappler-Guzzetta EA, Kalueff AV (2019) DARK Classics in Chemical Neuroscience: Atropine, Scopolamine, and Other Anticholinergic Deliriant Hallucinogens — ACS Chemical Neuroscience doi:10.1021/acschemneuro.8b00615
- [2]
- [3]
- [4]
- [5]
- [6]